Tower Research Capital LLC (TRC) - ALLOGENE THERAPEUTICS INC ownership

ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 169 filers reported holding ALLOGENE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 6.14 and the average weighting 0.1%.

Quarter-by-quarter ownership
Tower Research Capital LLC (TRC) ownership history of ALLOGENE THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$73,593
+171.1%
31,585
+420.2%
0.00%0.0%
Q1 2024$27,142
-85.4%
6,072
-89.5%
0.00%
-50.0%
Q4 2023$185,528
+609.5%
57,797
+600.7%
0.00%
+100.0%
Q3 2023$26,149
-61.4%
8,249
-39.5%
0.00%
-50.0%
Q2 2023$67,761
+161235.7%
13,634
+61.7%
0.00%
+100.0%
Q1 2023$42
-59.6%
8,434
-48.7%
0.00%
-75.0%
Q4 2022$104
-100.0%
16,454
-39.7%
0.00%
-20.0%
Q3 2022$295,000
+40.5%
27,278
+48.0%
0.01%0.0%
Q2 2022$210,000
-13.6%
18,427
-30.9%
0.01%
+150.0%
Q1 2022$243,000
+10.0%
26,665
+80.1%
0.00%
-50.0%
Q4 2021$221,000
-30.1%
14,806
+20.3%
0.00%
-50.0%
Q3 2021$316,000
+95.1%
12,307
+97.5%
0.01%
+100.0%
Q2 2021$162,000
-11.0%
6,230
+20.6%
0.00%
+33.3%
Q1 2021$182,000
+36.8%
5,165
-2.0%
0.00%
-25.0%
Q4 2020$133,000
+2.3%
5,272
+53.3%
0.00%
+300.0%
Q3 2020$130,000
-76.6%
3,439
-73.5%
0.00%
-95.7%
Q2 2020$556,000
+55500.0%
12,983
+20185.9%
0.02%
Q1 2020$1,000
-99.1%
64
-98.5%
0.00%
-100.0%
Q4 2019$110,000
+41.0%
4,216
+46.5%
0.01%
+80.0%
Q3 2019$78,000
+3800.0%
2,878
+3789.2%
0.01%
Q2 2019$2,000740.00%
Other shareholders
ALLOGENE THERAPEUTICS INC shareholders Q4 2023
NameSharesValueWeighting ↓
Vida Ventures Advisors, LLC 1,798,163$26,829,00010.04%
Wildcat Capital Management, LLC 1,716,370$25,608,0004.17%
TPG GP A, LLC 18,716,306$279,247,0002.79%
Casdin Capital, LLC 2,650,000$39,538,0001.11%
Lombard Odier Asset Management (Switzerland) SA 996,116$14,862,0000.95%
Coastal Bridge Advisors, LLC 301,929$4,505,0000.94%
HARBOR CAPITAL ADVISORS, INC. 119,547$1,784,0000.65%
Pier Capital, LLC 294,968$4,401,0000.46%
Navalign, LLC 64,428$961,0000.38%
Gratus Capital, LLC 191,871$2,863,0000.26%
View complete list of ALLOGENE THERAPEUTICS INC shareholders